-
FIRMAGON® has a significantly greater probability of PSA recurrence-free survival than leuprolide in prostate cancer patients
-Results from a phase III pivotal study sub-analyses reported in European Urology show that…
0 -
Launch of FIRMAGON
-Launch of FIRMAGON® (degarelix), a GnRH blocker for advanced hormone-dependent prostate cancer.
Archive for December, 2009
2009 > December